GipsonJD, KoenigMA, HindinMJ. The effects of unintended pregnancy on infant, child, and parental health: A review of the literature. Stud Fam Plann, 2008; 39(1):18–38; doi: 10.1111/j.1728-4465.2008.00148.x
2.
DehlendorfC, HarrisLH, WeitzTA. Disparities in abortion rates: A public health approach. Am J Public Health, 2013; 103(10):1772–1779; doi: 10.2105/AJPH.2013.301339
3.
BradleySEK, PolisCB, MicksEA, et al.Effectiveness, safety, and comparative side effects. In: Contraceptive Technology. 22nd edition. (CasonP, CwiakC, EdelmanA eds). Jones & Bartlett Learning; 2023; pp. 130–131.
4.
BrandiK, UpadhyaKK, TealSB. Over-the-counter oral contraception as an opportunity to reduce contraceptive access inequity. JAMA, 2023; 330(5):407–408; doi: 10.1001/jama.2023.10825
5.
RiveraR, YacobsonI, GrimesD. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol, 1999; 181(5 Pt 1):1263–1269; doi: 10.1016/s0002-9378(99)70120-1
GlasierA, SoberS, GasloliR, et al.A review of the effectiveness of a progestogen-only pill containing norgestrel 75 µg/day. Contraception, 2022; 105:1–6; doi: 10.1016/j.contraception.2021.08.016
8.
Centers for Disease Control and Prevention (CDC). U S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep, 2010; 59(RR-4):1–86.
9.
TepperNK, WhitemanMK, MarchbanksPA, et al.Progestin-only contraception, and thromboembolism: A systematic review. Contraception, 2016; 94(6):678–700; doi: 10.1016/j.contraception.2016.04.014
GrindlayK, KeyK, ZunigaC, et al.Interest in continued use after participation in a Study of Over-the-Counter progestin-only pills in the United States. Womens Health Rep (New Rochelle), 2022; 3(1):904–914; doi: 10.1089/whr.2022.0056
